Manuel Hidalgo, MD, PhD, professor of medicine, Harvard Medical School, chief, Department of Hematology/Oncology, Beth Israel Deaconess Medical Center, discusses the phase III TRYbeCA1 trial in patients with advanced pancreatic adenocarcinoma.
Manuel Hidalgo, MD, PhD
Advertisement
Articles by Manuel Hidalgo, MD, PhD
Advertisement
Latest Updated Articles
Dr. Hidalgo Discusses the Phase III TRYbeCA1 Trial in Pancreatic CancerNovember 27th 2018
Advertisement
Advertisement
Trending on OncLive
1
MONUMENTAL-3 Data Support Talquetamab Plus Daratumumab ± Pomalidomide as a New SOC in R/R Myeloma
2
FDA Approves Capivasertib Plus Abiraterone and Prednisone for PTEN-Deficient mHSPC
3
Luspatercept Misses Primary RBC-TI End Point But Shows Clinically Meaningful Improvement for Anemia in Myelofibrosis
4
CLL14 Final Analysis Shows Long-Term PFS Gain With Venetoclax/Obinutuzumab in Previously Untreated CLL
5